RedHill Biopharma (RDHL)
NASDAQ:RDHL
Want to see RDHL full AI Analyst Report?
RDHL Stock Chart & Stats
$1.20
-$0.32(-4.91%)
At close: 4:00 PM EST
$1.20
-$0.32(-4.91%)
Day’s Range― - ―
52-Week Range$0.71 - $3.31
Previous CloseN/A
Volume5.64K
Average Volume (3M)1.98M
Market Cap
$5.19M
Enterprise Value$241.86K
Total Cash (Recent Filing)$2.87M
Total Debt (Recent Filing)$214.00K
Price to Earnings (P/E)―
Beta1.48
Next Earnings
Aug 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-4.00
Shares Outstanding5,191,260
10 Day Avg. Volume104,605
30 Day Avg. Volume1,981,143
Financial Highlights & Ratios
PEG Ratio0.08
Price to Book (P/B)0.76
Price to Sales (P/S)11.38
P/FCF Ratio-0.34
Enterprise Value/Market Cap0.05
Enterprise Value/Revenue0.03
Enterprise Value/Gross Profit0.04
Enterprise Value/Ebitda-0.03
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)$50.60M
Bulls Say, Bears Say
Bulls Say
Talicia Market PositionTalicia’s leading branded position and long patent exclusivity through 2042, plus a joint U.S. commercialization vehicle with Cumberland, provide a durable, protected revenue stream and a commercial platform to expand U.S. uptake and generate licensing or royalty income abroad.
RHB-204 Pipeline PotentialRHB-204 builds on prior Phase 3 proof for RHB-104 and shows comparable MAP-killing at lower doses preclinically. A targeted Phase 2 in MAP-positive Crohn’s patients could unlock a differentiated oral therapy addressing a clear unmet need and improve partnership and non-dilutive funding prospects.
Balance-sheet RepairReduced leverage and a swing to positive equity in 2025 (with ~$4.1M cash) materially improve solvency and financing optionality versus prior years, lowering immediate insolvency risk and supporting continued program advancement or commercialization while management pursues partnerships.
Bears Say
Revenue Collapse & LossesA dramatic top-line decline to $0.3M in 2025 and recurring operating losses undercut scale economics and the firm’s ability to self-fund R&D or commercialization. Structural revenue weakness raises execution risk for pipeline programs and increases reliance on external capital or partners.
Persistent Cash BurnSustained negative operating and free cash flow indicate ongoing cash consumption that necessitates external financing or asset monetization. Over the medium term this can force dilution, delay trials or partnerships, and constrain the company’s ability to execute its clinical and commercial plans independently.
Listing & Dilution RiskA Nasdaq deficiency notice creates structural liquidity and market-access risk; management may be compelled to pursue share-based remedies or other actions. Coupled with an approved increase in authorized share capital, this raises the probability of future dilution as a tool to shore up financing or meet listing criteria.
RedHill Biopharma News
RDHL FAQ
What was RedHill Biopharma’s price range in the past 12 months?
RedHill Biopharma lowest stock price was $0.71 and its highest was $3.31 in the past 12 months.
What is RedHill Biopharma’s market cap?
RedHill Biopharma’s market cap is $5.19M.
When is RedHill Biopharma’s upcoming earnings report date?
RedHill Biopharma’s upcoming earnings report date is Aug 20, 2026 which is in 79 days.
How were RedHill Biopharma’s earnings last quarter?
Currently, no data Available
Is RedHill Biopharma overvalued?
According to Wall Street analysts RedHill Biopharma’s price is currently Overvalued.
Does RedHill Biopharma pay dividends?
RedHill Biopharma does not currently pay dividends.
What is RedHill Biopharma’s EPS estimate?
RedHill Biopharma’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does RedHill Biopharma have?
RedHill Biopharma has 5,191,260 shares outstanding.
What happened to RedHill Biopharma’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of RedHill Biopharma?
Currently, no hedge funds are holding shares in RDHL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
RedHill Biopharma
RedHill Biopharma Ltd. is a specialty biopharmaceutical company focused on the development and commercialization of innovative therapies for gastrointestinal diseases and cancer. The company operates primarily in the biopharmaceutical sector, with a strong emphasis on creating oral drug formulations that address unmet medical needs. RedHill's core products include therapies targeting conditions such as peptic ulcers, inflammatory bowel disease, and other gastrointestinal disorders, as well as oncology treatments.
Technical Analysis
China Pharma Holdings
―
Sonoma Pharmaceuticals
―
PainReform
―
Universe Pharmaceuticals
―
Shuttle Pharmaceuticals Holdings, Inc.
―
Ownership Overview
― Insiders
―
Mutual Funds
9.25% Other Institutional Investors
90.75% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---